Travere Therapeutics (TVTX) Interest Expenses (2011 - 2026)

Travere Therapeutics (TVTX) has 16 years of Interest Expenses data on file, last reported at $2.3 million in Q1 2026.

• Quarterly Interest Expenses fell 20.69% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (up 13.72% YoY) and the FY2025 annual result came in at $370.6 million, up 7.68% from the prior year.
• Interest Expenses improved to $2.3 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $21.8 million in Q2 2025 to a low of $438000.0 in Q4 2024.
• A 5-year average of $3.7 million and a median of $2.8 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses tumbled 84.36% — and 2025, when it soared 683.11%.
• Tracing TVTX's Interest Expenses over 5 years: stood at $2.8 million in 2022, then retreated by 0.5% to $2.8 million in 2023, then slumped by 84.36% to $438000.0 in 2024, then surged by 402.28% to $2.2 million in 2025, then increased by 4.55% to $2.3 million in 2026.
• The last three Interest Expenses figures came in at $2.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.